evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, Oskar Hansson, Mary Sano, Filip Krag Knop, Peter Johannsen, Teresa León, Philip Scheltens
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1186/s13195-024-01666-7
- Published
- Jan 8, 2025
- Venue
- Alzheimer s Research & Therapy
- DOI
- 10.1186/s13195-024-01666-7
- PubMed
- 39780249
- Categories
- Alzheimer's disease research and treatments
- License
- cc-by-nc-nd
- Provenance
- openalex